|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM105371874 |
| 003 |
DE-627 |
| 005 |
20231222134527.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0352.xml
|
| 035 |
|
|
|a (DE-627)NLM105371874
|
| 035 |
|
|
|a (NLM)10607490
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wither, J E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.01.2000
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2000 Academic Press.
|
| 520 |
|
|
|a Polyclonal B cell activation is a hallmark of autoimmune disease in NZB and (NZB x NZW)F(1) (NZB/W) mice. However, the mechanism by which this activated cell subset facilitates disease development is unknown. We recently showed that resting B cells from these mice demonstrate enhanced expression of costimulatory molecules in response to CD40 crosslinking (Jongstra-Bilen et al., J. Immunol. 159,5810-5820, 1997). This led us to question whether activated B cells expressed costimulatory molecules in vivo. Using flow cytometry we found that NZB and NZB/W mice have an increased proportion of splenic B cells expressing B7.1 and elevated levels of B7.2 and ICAM-1. These B cells isolate within the low-density activated population and possess the phenotypic characteristics of marginal zone B cells. The levels of B7.1 on the activated B cell population are similar to those induced by CD40 stimulation raising the possibility that activated B cells in NZB and NZB/W mice provide costimulatory signals to self-reactive T cells leading to loss of tolerance
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, Differentiation, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Surface
|2 NLM
|
| 650 |
|
7 |
|a B7-1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD40 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Ligands
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a CD40 Ligand
|2 NLM
|
| 650 |
|
7 |
|a 147205-72-9
|2 NLM
|
| 650 |
|
7 |
|a Percoll
|2 NLM
|
| 650 |
|
7 |
|a 65455-52-9
|2 NLM
|
| 650 |
|
7 |
|a Silicon Dioxide
|2 NLM
|
| 650 |
|
7 |
|a 7631-86-9
|2 NLM
|
| 650 |
|
7 |
|a Povidone
|2 NLM
|
| 650 |
|
7 |
|a FZ989GH94E
|2 NLM
|
| 700 |
1 |
|
|a Roy, V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brennan, L A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 94(2000), 1 vom: 15. Jan., Seite 51-63
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:94
|g year:2000
|g number:1
|g day:15
|g month:01
|g pages:51-63
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 94
|j 2000
|e 1
|b 15
|c 01
|h 51-63
|